BetaGlue Technologies

What BetaGlue Technologies does

BetaGlue Therapeutics S.p.A. (formerly BetaGlue Technologies, rebranded April 2024) is an Italian clinical-stage oncology company headquartered in Milan developing YntraDose, a locoregional radiotherapy platform for unresectable solid tumors. The technology combines Yttrium-90 microspheres with Artivion's BioGlue — a biocompatible surgical adhesive used in over 2.5 million procedures — that polymerizes within 120 seconds after percutaneous injection, immobilizing the radioactive payload at the tumor site and preventing migration to surrounding tissue. The platform is delivered as a four-component system (YntraDose-90, -Guide, -Glue, -Deliver) and is positioned as a minimally invasive alternative to external beam radiotherapy (SBRT/PBRT), bypassing the need for specialized capital equipment. The lead clinical indication is unresectable locally advanced pancreatic ductal adenocarcinoma (uLA-PDAC), with concurrent pipeline programs in hepatocellular carcinoma (78% progress), ductal carcinoma in situ (77%), and immuno-oncology (20%).

The company is pre-revenue and pre-commercial — YntraDose is not approved for human use or sale — and currently monetizes only via its research and grant funding model. It has secured cumulative funding above €30M, including a €10M equity round in 2022, a €10M EIC Accelerator Award in March 2024 (one of 42 of 1,083 applicants), an €8M equity round led by Neva SGR and LIFTT in June 2024, and a €6M investment from Italy's ENEA-Tech Biomedical Foundation in December 2024. BetaGlue has obtained clinical trial authorizations from MHRA (UK, November 2025), the Italian Ministry of Health (December 2025), and the Belgium Ministry of Health (December 2025), with first patient enrollment targeted for early 2026. Go-to-market is enterprise field sales into interventional oncology centers, supported by conference presence (ASCO, CIRSE, SIR, JPM Healthcare), ISO 13485 certification, and an exclusive global BioGlue supply partnership with Artivion.

Name

BetaGlue Technologies

Legal name

BETAGLUE THERAPEUTICS S.P.A.

Website

https://betaglue.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

BetaGlue Therapeutics is an Italian clinical-stage oncology company developing YntraDose, a Yttrium-90 radiotherapy platform embedded in Artivion's BioGlue matrix for percutaneous treatment of unresectable solid tumors, primarily pancreatic cancer.

Ownership category

akta.pro rank

Product category

Interventional Oncology Devices

NAICS

Irradiation Apparatus Manufacturing (334517)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

akta.pro secondary industry

Radiation Oncology (HLAKAFAC)

Keywords

• Radiotherapy devices
• Interventional oncology
• Nuclear medicine
• Targeted cancer therapy
• Medical device manufacturing

Headquarters

HQ city

Milano

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. YntraDose Radiotherapy Platform: BetaGlue is a clinical-stage company developing the YntraDose radiotherapy platform for treating solid tumors. As a pre-commercial company, revenue is not yet generated. The company is pursuing regulatory approval for clinical trials and eventual commercialization of its therapeutic platform for cancer treatment.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

BetaGlue Therapeutics is developing YntraDose, a clinical-stage locoregional radiotherapy platform that delivers Yttrium-90 microspheres embedded in a biocompatible adhesive glue matrix directly into solid tumors via percutaneous injection. The glue polymerizes within 120 seconds, retaining radioactive microspheres at the tumor site to enable localized radiation while sparing surrounding healthy tissue. The platform comprises four components: YntraDose-90 (microspheres), YntraDose-Guide, YntraDose-Glue, and YntraDose-Deliver injection system.

Product overview

BetaGlue Therapeutics offers YntraDose®, a targeted nuclear radiotherapy platform for treating solid tumors. The platform is comprised of four integrated components: YntraDose-90 (Yttrium-90 microspheres), YntraDose-Guide (guidance system), YntraDose-Glue (biocompatible adhesive matrix supplied by Artivion), and YntraDose-Deliver (injection system). Formerly known as BAT-90, the therapy delivers radiation directly into tumors via percutaneous injection, with the glue matrix immobilizing the radioactive microspheres at the treatment site. The company is a clinical-stage oncology company developing this locoregional radiotherapy solution primarily targeting pancreatic cancer (LA-PDAC), with pipeline potential for liver, breast, and other solid tumor indications.

Differentiator

Problem solved

Functional benefit

Brands

• YntraDose: Innovative Yttrium-90 microsphere radiotherapy solution for targeted and personalised treatment of solid tumours. The platform comprises YntraDose-90, YntraDose-Guide, YntraDose-Glue, and YntraDose-Deliver components. Formerly known as BAT-90.
• YntraDose-90
• YntraDose-Guide
• YntraDose-Glue
• YntraDose-Deliver

Products and services

• YntraDose Radiotherapy Platform A targeted nuclear therapy platform combining biotechnology, nuclear science, and interventional oncology to deliver Yttrium-90 microspheres directly into solid tumors via a biocompatible glue matrix. Designed for interventional radiologists and cancer treatment centers treating unresectable solid tumors including pancreatic cancer (LA-PDAC), liver cancer (HCC), and breast cancer (DCIS).

Quantifiable outcome

• Polymerization occurs within 120 seconds, preventing microsphere spread to surrounding tissues
• +1 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Fondazione Policlinico Universitario Agostino Gemelli IRCCScoreStrategic or Co-development Partner · 1 December 2025Clinical trial site for YntraDose in unresectable locally advanced pancreatic cancer (uLA-PDAC) in Italy. BetaGlue expanded its clinical trial in Italy after obtaining approval from the Italian Ministry of Health, with the study to be conducted at this Rome-based institution.
• Artivion Inc.coreOEM/ Whitelabel/ Licensing Partner · 20 February 2025BetaGlue entered into a long-term exclusive global supply agreement with Artivion for the supply of BioGlue, a surgical sealant used in the manufacture of YntraDose. Artivion manufactures, markets, and sells BioGlue in over 80 countries. The agreement secures the manufacture and supply of the key component for YntraDose's glue matrix technology. YntraDose enables minimally-invasive needle-based focal high-radiation treatment of solid tumors by 'holding' and 'gluing' radioactive microspheres at the site of administration.
• Cohesion LabsminorImplementation/ SI/ Consulting Partner · 30 April 2024UK-based creative agency that collaborated with BetaGlue to deliver the new website and complete rebrand from BetaGlue Technologies to BetaGlue Therapeutics, including the product name change to YntraDose.

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Boston Scientific (TheraSphere): Boston Scientific acquired TheraSphere (Yttrium-90 glass microspheres) in 2019 for $4.1B. TheraSphere is the leading FDA-approved Y-90 radioembolization therapy for liver cancer and the most direct competitive incumbent to BetaGlue's YntraDose platform in the Y-90 category.
• Advanced Accelerator Applications (Novartis): AAA (a Novartis company) is the global leader in therapeutic radiopharmaceuticals (Lutathera, Pluvicto). Multiple BetaGlue executives are former AAA leaders, and AAA's commercial radioligand infrastructure represents both the competitive landscape and the most likely strategic acquirer profile.
• Lantheus Holdings: Lantheus is an established radiopharmaceutical company with diagnostic imaging agents (DEFINITY, Xenon-133) and is expanding into therapeutic radiopharmaceuticals. Comparable as a strategic incumbent in the broader radiopharmaceutical oncology space.
• Bayer (Radiopharmaceuticals): Bayer markets Xofigo (Radium-223) for prostate cancer bone metastases and is investing in targeted radionuclide therapies through its radiopharmaceutical platform. Comparable as a large strategic player in therapeutic radiopharmaceuticals.

Direct peers

• Sirtex Medical (SIR-Spheres): Sirtex markets SIR-Spheres Y-90 resin microspheres, the other major approved Y-90 radioembolization product globally. Direct competitor to BetaGlue in Y-90-based liver tumor therapy, with extensive real-world clinical evidence and a global sales infrastructure.
• Terumo (Quirem Medical): Terumo acquired Quirem Medical and offers QuiremSpheres, a Holmium-166 radioembolization platform. Comparable to BetaGlue as a next-generation targeted radiotherapy company developing microsphere-based locoregional cancer therapies.

Emerging players

• Telix Pharmaceuticals: Telix is a commercial-stage radiopharmaceutical company developing diagnostic and therapeutic agents (Illuccix, TLX591) for oncology. Comparable as a peer radiopharma oncology company at a similar development stage but with approved products generating revenue.
• ABK Biomedical: ABK Biomedical is a clinical-stage company developing Eye90 microspheres, a Y-90 radioembolic platform for uveal melanoma and other tumors. Comparable to BetaGlue as a smaller clinical-stage company developing novel Y-90-based locoregional radiotherapy products.
• ITM Isotope Technologies Munich: ITM is a clinical-to-commercial stage radiopharmaceutical company developing targeted radionuclide therapies (e.g., Solucin for GEP-NETs). Comparable as a European-based therapeutic radiopharma peer at a more advanced clinical stage.

Others

• Curium Pharma: Curium is one of the world's largest radiopharmaceutical manufacturers, supplying diagnostic and therapeutic isotopes (including Y-90) globally. Comparable as an adjacent ecosystem player — both a potential supplier partner and indirect competitor in the nuclear medicine value chain.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights3 records

Customer concentration

• LinkedInlinkedin.com/company/betaglue-technologies

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds4 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BetaGlue Technologies